Androgen receptor functioned as a suppressor in the prostate cancer cell line PC3 in vitro and in vivo

Chinese Medical Journal

Volumn 122, Issue 22, 2009, Pages 2779-2783

  Yu, Sheng Qiang ^a   Han, Bang Min ^a   Shao, Yi ^a   Wu, Ji Tao ^a   Zhao, Fu Jun ^a   Liu, Hai Tao ^a   Sun, Xiao Wen ^a   Tang, Yue Qing ^a   Xia, Shu Jie ^a  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

Author keywords

Androgen independent; Androgen receptor; Orthotopic xenograft; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER INVASION; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PROSTATE CANCER; TUMOR XENOGRAFT; WOUND HEALING;

ANIMALS; CELL LINE, TUMOR; HUMANS; MALE; MICE; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TRANSPLANTATION, HETEROLOGOUS; TUMOR SUPPRESSOR PROTEINS;

EID: 73449117244     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.22.020     Document Type: Article

References (24)

1. Ian LH, Li H, Yang Y, Ho CF. Comparisons of the incidence and pathological characteristics of prostate cancer between Chinese and Portuguese in Macau. Chin Med J 2008; 121: 292-294.
2. Na YQ. Are we ready for prostate cancer? Chin Med J 2008; 121: 291.
3. Ho SF, Lao HF, Li K, Tse MK. Clinical results of radical prostatectomy for patients with prostate cancer in Macau. Chin Med J 2008; 121: 295-298.
4. Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate 2004; 61: 332-353.
5. Yang Y. Treatment of the positive surgical margin following radical prostatectomy. Chin Med J 2008; 121: 375-379.
6. Hu MQ, Na YQ. Metabolism of adrenal androgen and its impacts on prostate cancer after castration. Chin Med J 2008; 121: 369-374.
7. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10: 33-39.
8. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004; 25: 276-308.
9. Edwards J, Krishna NS, Grigor KM, Bartlett JM. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 2003; 89: 552-556.
10. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979; 17: 16-23.
11. Xu XF, Zhou SW, Zhang X, Ye ZQ, Zhang JH, Ma X, et al. Prostate androgen-regulated gene: a novel potential target for androgen-independent prostate cancer therapy. Asian J Androl 2006; 8: 455-462.
12. Yu SQ, Lai KP, Xia SJ, Chang HC, Chang C, Yeh S. The diverse and contrasting effects of using human prostate cancer cell lines to study androgen receptor roles in prostate cancer. Asian J Androl 2009; 11: 39-48.
13. Diallo JS, Peant B, Lessard L, Delvoye N, Le Page C, Mes-Masson AM, et al. An androgen-independent androgen receptor function protects from inositol hexakisphosphate toxicity in the PC3/PC3 (AR) prostate cancer cell lines. Prostate 2006; 66: 1245-1256.
14. Yuan S, Trachtenberg J, Mills GB, Brown TJ, Xu F, Keating A. Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA. Cancer Res 1993; 53: 1304-1311.
15. Heisler LE, Evangelou A, Lew AM, Trachtenberg J, Elsholtz HP, Brown TJ. Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor. Mol Cell Endocrinol 1997; 126: 59-73.
16. Altuwaijri S, Wu CC, Niu YJ, Mizokami A, Chang HC, Chang C. Expression of human AR cDNA driven by its own promoter results in mild promotion, but not suppression, of growth in human prostate cancer PC-3 cells. Asian J Androl 2007; 9: 181-188.
17. Jiang J, Wang LF, Fang YH, Jin FS, Jin WS. Proliferative response of human prostate cancer cell to hormone inhibited by androgen receptor antisense RNA. Chin Med J 2004; 117: 684-688.
18. Liu RL, Zhang ZH, Zhao WM, Wang M, Qi SY, Li J, et al. Expression of nucleostemin in prostate cancer and its effect on the proliferation of PC-3 cells. Chin Med J 2008; 121: 299-304.
19. van Weerden WM, Romijn JC. Use of nude mouse xenograft models in prostate cancer research. Prostate 2000; 43: 263-271.
20. Sato N, Gleave ME, Bruchovsky N, Rennie PS, Beraldi E, Sullivan LD. A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice. Cancer Res 1997; 57: 1584-1589.
21. Tuomela JM, Valta MP, Vaananen K, Harkonen PL. Alendronate decreases orthotopic PC-3 prostate tumor growth and metastasis to prostate-draining lymph nodes in nude mice. BMC Cancer 2008; 8: 81.
22. Liu D, Hornsby PJ. Fibroblast stimulation of blood vessel development and cancer cell invasion in a subrenal capsule xenograft model: stress-induced premature senescence does not increase effect. Neoplasia 2007; 9: 418-426.
23. 125I labeled triple-helix forming oligonucleotide directed against androgen receptor. Chin Med J 2008; 121: 2284-2289.
24. Scaccianoce E, Festuccia C, Dondi D, Guerini V, Bologna M, Motta M, et al. Characterization of prostate cancer DU145 cells expressing the recombinant androgen receptor. Oncol Res 2003; 14: 101-112.